News | May 01, 2025
Briefs: Alembic Pharmaceuticals and Bafna Pharmaceuticals
Alembic Pharmaceuticals commissions new facility at Pithampur
Alembic Pharmaceuticals commissions new facility at Pithampur
This approval authorizes the company to export Ibuprofen to the Chinese markets
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Bayer expects 2025 to be the most difficult year of its turnaround
The implementation, spearheaded by Deloitte Consulting, brings together domain expertise and cutting-edge technology
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
This unit will focus on the manufacturing of health and wellness equipment
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
Subscribe To Our Newsletter & Stay Updated
